Categories: NewsPharmaceutical

Eyenovia to Report Third Quarter 2022 Results on Thursday, November 10

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Company to host an investor conference call and webcast at 4:30pm ET on that day

NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced that the Company will release financial results for the third quarter ended September 30, 2022 on Thursday, November 10, 2022, after the markets close. Following the release, Eyenovia management will host a conference call to review the financial and operating results.

The conference call is scheduled to begin at 4:30pm ET on Thursday, November 10, 2022. Participants should dial 1-866-575-6539 (domestic) or 1-929-477-0448 (international) with the conference code 1600616. A live webcast of the conference call will also be available on the investor relations page of the Company’s corporate website at www.eyenovia.com.

After the live webcast, the event will be archived on Eyenovia’s website for one year.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia, and myopia progression. For more information, visit www.eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Eyenovia Contact:
Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:
Eyenovia, Inc.
Norbert Lowe
Vice President, Commercial Operations
nlowe@eyenovia.com

Staff

Recent Posts

Croom Lawrence Joins Hemostemix with Revenue Share Agreement and VesCell.Health Launch

Calgary, Alberta--(Newsfile Corp. - June 27, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a…

3 hours ago

Hazelden Betty Ford Mourns the Loss of Addiction Advocate Bill Moyers

Center City, Minnesota--(Newsfile Corp. - June 27, 2025) - The Hazelden Betty Ford Foundation expresses…

3 hours ago

Trella Health Launches Its Latest Medicare Advantage (MA) Data to Help Post-Acute Providers Thrive in the Expanding MA Market

Now available in Marketscape Insights, this upgraded dataset delivers greater visibility into Medicare Advantage referral…

3 hours ago

Qaelon Medical Establishes Data Advisory Board to Revolutionize Surgical Leak Detection

STRASBOURG, France, June 27, 2025 /PRNewswire/ -- Qaelon Medical, a pioneer in real-time surgical leak…

3 hours ago

Jesse Draper’s Halogen Ventures Announces the Close of $30 Million Fund to Invest in Childcare and the Future of Family

Third fund taps into a $7.5 trillion dollar market opportunity to provide solutions for modern…

3 hours ago

Core Solutions & OPEN MINDS Announce Launch of AI Advisory Board to Revolutionize Behavioral Health with Ethical AI Practices

KING OF PRUSSIA, Pa., June 27, 2025 /PRNewswire/ -- Core Solutions (Core), a leader in AI-enhanced…

3 hours ago